Figure 1.

Associations of KRAS mutations with survival in the stage IV adenocarcinomas from the NSCLC cohort. (A) HRs with corresponding 95% Bonferroni CIs for each specific KRAS mutation type occurring in at least 10 patients, as assessed via Cox proportional hazards regression models adjusting for age and sex. (B) Kaplan-Meier curves with 95% CIs for patients with wild-type KRAS and patients with any kind of KRAS mutation, and Kaplan-Meier curves for patients with wild-type KRAS, patients with G12C mutations, and patients with G12V mutations. (C) Loadings matrix for the second through fifth principal component found from applying B-PCA to mutation data in the stage IV adenocarcinomas of the NSCLC cohort. (D) Kaplan-Meier curves comparing the patients in five clusters, derived from clustering the patient scores for the principal components. (E) Heatmap showing mutation patterns among the genes differentially mutated (FDR < 0.05) across the five clusters.